Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 3, 2026, 4:18 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 48 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: Intranasal insulin Clear all
Completed Phase 1 Interventional Results available

Investigation of the Safety of Intranasal Glulisine in Down Syndrome

NCT02432716
View directory record Official record
Conditions
Down Syndrome
Interventions
Insulin glulisine, Saline
Drug
Lead sponsor
HealthPartners Institute
Other
Eligibility
35 Years to 80 Years
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2018
U.S. locations
1
States / cities
Saint Paul, Minnesota
Source: ClinicalTrials.gov public record
Updated Dec 5, 2019 · Synced Sep 3, 2026, 4:18 PM EDT
Completed Phase 2 Interventional Results available

Intranasal Insulin for Posttraumatic Stress Disorder

NCT04044534
View directory record Official record
Conditions
PTSD
Interventions
Intranasal insulin, Placebo
Drug
Lead sponsor
VA Connecticut Healthcare System
Federal
Eligibility
21 Years to 65 Years
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
1
States / cities
West Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Jul 12, 2026 · Synced Sep 3, 2026, 4:18 PM EDT
Recruiting Phase 1Phase 2 Interventional

Intranasal Insulin for Treatment of Alcohol Use Disorder

NCT05988632
View directory record Official record
Conditions
Alcohol Use Disorder
Interventions
Regular Human Insulin then Placebo, Placebo then Regular Human Insulin
Drug
Lead sponsor
Brown University
Other
Eligibility
21 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
1
States / cities
Providence, Rhode Island
Source: ClinicalTrials.gov public record
Updated Sep 4, 2025 · Synced Sep 3, 2026, 4:18 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Dose-Finding Study of Intranasal Insulin in Healthy Participants Insulin in Healthy Participants

NCT05062785
View directory record Official record
Conditions
Out-Of-Hospital Cardiac Arrest, Healthy
Interventions
Intranasal insulin
Drug
Lead sponsor
Robert Silbergleit
Other
Eligibility
18 Years and older
Enrollment
24 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2022
U.S. locations
1
States / cities
Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated Mar 26, 2026 · Synced Sep 3, 2026, 4:18 PM EDT
Terminated Phase 1 Interventional Accepts healthy volunteers Results available

Measurement of Insulin Levels in Cerebral Spinal Fluid (CSF) of Healthy Adults After a Single Intranasal Dose

NCT05866367
View directory record Official record
Conditions
Healthy
Interventions
Low dose Regular Insulin, High dose Regular insulin
Drug
Lead sponsor
HealthPartners Institute
Other
Eligibility
18 Years to 35 Years
Enrollment
2 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2024
U.S. locations
1
States / cities
Saint Paul, Minnesota
Source: ClinicalTrials.gov public record
Updated Nov 17, 2025 · Synced Sep 3, 2026, 4:18 PM EDT
Withdrawn Phase 1Phase 2 Interventional

Post Operative Delirium Study

NCT04635774
View directory record Official record
Conditions
Delirium
Interventions
Insulin, Saline
Drug
Lead sponsor
University of Kansas Medical Center
Other
Eligibility
65 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
1
States / cities
Kansas City, Kansas
Source: ClinicalTrials.gov public record
Updated Aug 20, 2024 · Synced Sep 3, 2026, 4:18 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Food Intake and Intra-Nasal Insulin for African American Adults (FIINAAL)

NCT04739371
View directory record Official record
Conditions
Insulin
Interventions
Insulin, Regular, Human, Placebo
Drug
Lead sponsor
Pennington Biomedical Research Center
Other
Eligibility
45 Years to 65 Years
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2022
U.S. locations
1
States / cities
Baton Rouge, Louisiana
Source: ClinicalTrials.gov public record
Updated Nov 28, 2023 · Synced Sep 3, 2026, 4:18 PM EDT
Recruiting Phase 2 Interventional

Intranasal Insulin and Glutathione as an Add-On Therapy in Parkinson's Disease

NCT05266417
View directory record Official record
Conditions
Parkinson Disease
Interventions
INS-GSH, Matched Placebos
Drug
Lead sponsor
Gateway Institute for Brain Research
Industry
Eligibility
30 Years and older
Enrollment
56 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2027
U.S. locations
4
States / cities
Davie, Florida • Hialeah, Florida • Miami, Florida + 1 more
Source: ClinicalTrials.gov public record
Updated Jul 21, 2026 · Synced Sep 3, 2026, 4:18 PM EDT
Completed Phase 4 Interventional Results available

Intranasal Insulin Treatment in Patients With Schizophrenia

NCT00575666
View directory record Official record
Conditions
Schizophrenia
Interventions
Insulin or Placebo
Drug
Lead sponsor
University of Massachusetts, Worcester
Other
Eligibility
18 Years to 65 Years
Enrollment
45 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2010
U.S. locations
1
States / cities
Worcester, Massachusetts
Source: ClinicalTrials.gov public record
Updated Dec 16, 2012 · Synced Sep 3, 2026, 4:18 PM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

SNIFF Multi-Device Study 2

NCT04199767
View directory record Official record
Conditions
Mild Cognitive Impairment, Cognitive Impairment
Interventions
20 IU Humulin® R U-100 (NDC: 0002-8215, Eli Lilly & Company), 40 IU Humulin® R U-100 (NDC: 0002-8215, Eli Lilly & Company)
Drug
Lead sponsor
Wake Forest University Health Sciences
Other
Eligibility
55 Years to 85 Years
Enrollment
13 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020
U.S. locations
1
States / cities
Winston-Salem, North Carolina
Source: ClinicalTrials.gov public record
Updated Apr 1, 2026 · Synced Sep 3, 2026, 4:18 PM EDT
Not listed Phase 2 Interventional

Intranasal Insulin: A Novel Treatment for Gulf War Multisymptom Illness

NCT01802944
View directory record Official record
Conditions
Chronic Multisymptom Illness in Gulf War Veterans
Interventions
Intranasal Insulin, Placebos
Drug
Lead sponsor
Bronx Veterans Medical Research Foundation, Inc
Other
Eligibility
40 Years to 89 Years
Enrollment
114 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2017
U.S. locations
2
States / cities
Boston, Massachusetts • The Bronx, New York
Source: ClinicalTrials.gov public record
Updated Oct 5, 2017 · Synced Sep 3, 2026, 4:18 PM EDT
Terminated Phase 2 Interventional Results available

Intranasal Glulisine in Amnestic Mild Cognitive Impairment and Probable Mild Alzheimer's Disease

NCT02503501
View directory record Official record
Conditions
Mild Cognitive Impairment, Alzheimer's Disease (AD)
Interventions
Insulin glulisine, Placebo
Drug
Lead sponsor
HealthPartners Institute
Other
Eligibility
50 Years to 90 Years
Enrollment
49 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2019
U.S. locations
2
States / cities
Minneapolis, Minnesota • Saint Paul, Minnesota
Source: ClinicalTrials.gov public record
Updated Apr 8, 2020 · Synced Sep 3, 2026, 4:18 PM EDT
Terminated Phase 1Phase 2 Interventional Results available

Intranasal Insulin for the Treatment of HAND

NCT03081117
View directory record Official record
Conditions
HIV Dementia, HIV-Associated Cognitive Motor Complex
Interventions
Insulin, intranasal, Placebo, intranasal
Drug
Lead sponsor
Johns Hopkins University
Other
Eligibility
18 Years to 69 Years
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2020
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Jul 6, 2021 · Synced Sep 3, 2026, 4:18 PM EDT
Completed Phase 1Phase 2 Interventional Results available

Effect of Intranasal Insulin on LH Concentrations in Man

NCT02154477
View directory record Official record
Conditions
Hypogonadotropic Hypogonadism
Interventions
intranasal insulin, placebo (intranasal saline)
Drug
Lead sponsor
Texas Tech University Health Sciences Center
Other
Eligibility
18 Years to 75 Years · Male only
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2017
U.S. locations
1
States / cities
Odessa, Texas
Source: ClinicalTrials.gov public record
Updated Aug 12, 2019 · Synced Sep 3, 2026, 4:18 PM EDT
Recruiting Phase 2Phase 3 Interventional

Exercise and Intranasal Insulin in Type 2 Diabetes

NCT07675499
View directory record Official record
Conditions
Type 2 Diabetes, Insulin Sensitivity/Resistance, Cognition, Brain Blood Flow
Interventions
Intranasal Insulin, Intranasal Placebo, High Intensity Exercise
Drug · Behavioral
Lead sponsor
Rutgers, The State University of New Jersey
Other
Eligibility
55 Years to 80 Years
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2029
U.S. locations
4
States / cities
New Brunswick, New Jersey • Piscataway, New Jersey
Source: ClinicalTrials.gov public record
Updated Jun 29, 2026 · Synced Sep 3, 2026, 4:18 PM EDT
Withdrawn Phase 1 Interventional Accepts healthy volunteers

Measurement of Insulin Levels in the Cerebrospinal Fluid of Healthy Adults After a Single Intranasal Dose - Middle Age

NCT06434038
View directory record Official record
Conditions
Healthy
Interventions
Low Dose Regular insulin, High Dose Regular insulin, 0.9% Saline
Drug · Other
Lead sponsor
HealthPartners Institute
Other
Eligibility
36 Years to 55 Years
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2026
U.S. locations
1
States / cities
Saint Paul, Minnesota
Source: ClinicalTrials.gov public record
Updated Nov 24, 2025 · Synced Sep 3, 2026, 4:18 PM EDT
Terminated Phase 4 Interventional Accepts healthy volunteers Results available

Novel Approach for the Prevention of Hypoglycemia Associated Autonomic Failure (HAAF)

NCT03608163
View directory record Official record
Conditions
Diabetes Mellitus, Type 1, Hypoglycemia, Hypoglycemia Unawareness
Interventions
Naloxone, Diazoxide, Placebo (for Naloxone), Placebo (for Diazoxide)
Drug
Lead sponsor
Albert Einstein College of Medicine
Other
Eligibility
21 Years to 55 Years
Enrollment
4 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019
U.S. locations
1
States / cities
The Bronx, New York
Source: ClinicalTrials.gov public record
Updated Sep 10, 2025 · Synced Sep 3, 2026, 4:18 PM EDT
Not listed Phase 1 Interventional

PK/PD Study of Intranasal Insulin in Type I Diabetes

NCT01201278
View directory record Official record
Conditions
Type 1 Diabetes
Interventions
Insulin, Insulin LISPRO
Drug
Lead sponsor
Hompesch, Marcus, M.D.
Individual
Eligibility
18 Years to 65 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
1
States / cities
Chula Vista, California
Source: ClinicalTrials.gov public record
Updated Jun 16, 2011 · Synced Sep 3, 2026, 4:18 PM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Effects of Intranasal Insulin on Neuroimaging Markers and Cognition in Patients With Psychotic Disorders

NCT03943537
View directory record Official record
Conditions
Psychosis, Schizophrenia, Schizo Affective Disorder, Bipolar I Disorder
Interventions
Intranasal Insulin
Drug
Lead sponsor
Mclean Hospital
Other
Eligibility
18 Years to 40 Years
Enrollment
87 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2024
U.S. locations
1
States / cities
Belmont, Massachusetts
Source: ClinicalTrials.gov public record
Updated Sep 2, 2026 · Synced Sep 3, 2026, 4:18 PM EDT
Completed Phase 1 Interventional

Study of Nasal Insulin to Fight Forgetfulness - Short-Acting Insulin Aspart

NCT02462161
View directory record Official record
Conditions
Alzheimer's Disease, Mild Cognitive Impairment
Interventions
Insulin aspart, Placebo
Drug
Lead sponsor
Wake Forest University Health Sciences
Other
Eligibility
50 Years to 89 Years
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2019
U.S. locations
1
States / cities
Winston-Salem, North Carolina
Source: ClinicalTrials.gov public record
Updated Jul 27, 2025 · Synced Sep 3, 2026, 4:18 PM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Intranasal Insulin for Weight Management During Smoking Cessation

NCT02028871
View directory record Official record
Conditions
Tobacco Abstinence Syndrome
Interventions
Intranasal Insulin, Placebo
Drug
Lead sponsor
Ajna Hamidovic
Other
Eligibility
18 Years to 65 Years
Enrollment
26 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2016
U.S. locations
2
States / cities
Albuquerque, New Mexico
Source: ClinicalTrials.gov public record
Updated Dec 9, 2018 · Synced Sep 3, 2026, 4:18 PM EDT
Recruiting Phase 1 Interventional

Safety and Feasibility of Intranasal Insulin in Patients With Spinal Cord Injury

NCT07384052
View directory record Official record
Conditions
Spinal Cord Injury
Interventions
Regular Insulin, 0.9 % Normal Saline
Drug · Other
Lead sponsor
HealthPartners Institute
Other
Eligibility
18 Years to 84 Years
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026
U.S. locations
1
States / cities
Saint Paul, Minnesota
Source: ClinicalTrials.gov public record
Updated Mar 22, 2026 · Synced Sep 3, 2026, 4:18 PM EDT
Completed Phase 2 Interventional Results available

Intranasal Insulin and Post-stroke Cognition: A Pilot Study

NCT02810392
View directory record Official record
Conditions
Stroke
Interventions
Intranasal Insulin, Intranasal saline
Drug
Lead sponsor
Wake Forest University Health Sciences
Other
Eligibility
40 Years to 89 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2020
U.S. locations
1
States / cities
Winston-Salem, North Carolina
Source: ClinicalTrials.gov public record
Updated May 12, 2021 · Synced Sep 3, 2026, 4:18 PM EDT
Completed Phase 2 Interventional Results available

Cardiac Surgery Neuroprotection Study in Elders

NCT01561378
View directory record Official record
Conditions
Post-operative Cognitive Decline, Post-operative Delirium
Interventions
Aspart insulin, Normal saline, Intranasal mucosal atomizer device
Drug · Device
Lead sponsor
Albert Einstein College of Medicine
Other
Eligibility
65 Years and older
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
1
States / cities
The Bronx, New York
Source: ClinicalTrials.gov public record
Updated Nov 9, 2021 · Synced Sep 3, 2026, 4:18 PM EDT